Back to news

Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman

PR Newswire•19/11/2026•11:53 ET
0

Key Highlights

  • ➤Candel shares fell 26% after the company delayed its aglatimagene BLA submission.
  • ➤Aglatimagene BLA submission moved to middle of 2027, pending FDA dialogue and assay refinement.
  • ➤Candel previously said it remained on track for a Q4 BLA submission.
  • ➤Hagens Berman opened an investigation into Candel’s disclosures and potential federal securities-law violations.

Expert Statements

Reed Kathrein, Partner leading Hagens Berman’s investigation

“We're focused on how long Candel's assay refinement has been underway, and whether repeated 'on track' assurances may have intentionally misled investors”

Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman PR Newswire

SAN FRANCISCO, Nov. 19, 2026 /PRNewswire/ -- On November 13, 2026, investors in Candel Therapeutics (NASDAQ: CADL) saw the price of their shares tumble 26% on the company's announcement that it is delaying the submission of its biologics license application ("BLA") for its most advanced product candidate – aglatimagene, which is intended to treat patients with prostate cancer.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in